IMNM Company Profile and Key Details

Immunome, Inc. (NASDAQ:IMNM) closed at $25.82 USD, gaining $0.30 (1.18%) from the previous close of $25.52. The stock is currently mid-range between its 52-week high and low $8.66 and $27.65. With a market capitalization of about $2.47 billion, Immunome, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.07). Key stats such as the average daily volume over the past year has been around 1.38 million shares, volume is running light vs its 52-week average. Headquartered in Bothell, WA, Immunome, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Clay Siegall, the company employs approximately 177 people and listed since October 02, 2020. Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.

IMNM has shown sold momentum, gaining 16.09% over the past week and 52.39% over the past quarter, though year-to-date performance is up 11.17%. Short-term trend indicators are bearishly aligned (SMA20 -7.21%, SMA50 -3.65%, SMA200 49.17%). The stock’s 14-day RSI is 43.63 (neutral), while the ATR of 1.33 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -20.83% below its high and over 325.04% above its low. Average 10-day trading volume of 1.03 million shares is below the 3-month average of 1.32 million, indicating normal recent market interest.

Immunome, Inc. has 87.05 million shares outstanding. The public float is 70.81 million shares, elevated short interest at 17.06% of float. This equals 14.21 million shares. The short ratio is 12.83 days. Institutional investors hold 115.11% of the float. Insiders own 6.3%. SIEGALL CLAY B holds 690.70 thousand shares, WAGENHEIM PHILIP has 341.15 thousand shares and RAPP MICHAEL has 208.74 thousand shares. Over the past six months, insider transactions show net selling. They sold 402.75 thousand shares across 13 transactions.

Immunome, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $7.26. This means the shares are trading above this model’s fair value.

Immunome, Inc. generated EPS of -$2.96 over the past year. Five-year average earnings growth is -38.15%. Wall Street analysts project EPS growth of 24.09% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 10 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $18.00. The high target offers 54.92% upside. The low target suggests -30.29% downside. The mean target is $32.05. This offers 24.13% upside. Immunome, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -20.0%. The prior quarter beat by 27.08%. Over the last six quarters, Apple has recorded several small beats. These include 23.53% in March 19, 2025.

Immunome, Inc. trades at a P/E ratio of -10.7, slightly below the S&P 500 average, with a price-to-sales ratio of 609.12 and a price-to-book ratio of 4.92 trading at moderately above to book value. The P/FCF stands at -11.9, also below market averages.

Immunome, Inc. (NASDAQ:IMNM) shares are up 11.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Immunome, Inc. trading at a premium to the broader market with a P/E of -10.7. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $28.94, suggesting 12.08% upside. Our AI forecast model points to short-term weakness (-2.83% over two weeks), a medium-term rise (21.22% over three months), and a longer-term gain (9.53% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Immunome, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.83%, with price expected at $25.09 by August 19, 2026, within a range of $24.24 to $25.97 3-Month Outlook: Projected rise of 21.22%, reaching $31.30 by November 03, 2026, with a range of $30.99 to $31.71. 1-Year Outlook: Projected gain of 9.53%, with price at $28.28 by August 05, 2027, within a range of $26.49 to $30.20.